Search

Peptide therapeutics are one of the fastest-growing drug classes—but traditional synthesis methods often slow down innovation due to high costs, lengthy timelines, and purification bottlenecks.

Since its inception, ViroFend has focused on building an organization capable of translating a highly complex biomedical technology into the clinical setting, based on internationally leading

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size